# Fate Therapeutics

iPSC-NK 平台——来自单一细胞系的标准批次。

Source: https://cn.bioecon.ru/companies/fate-therapeutics/
Updated: 2026-06-24

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 截至2025年12月31日，现金、现金等价物及投资合计$2.051亿 | https://last10k.com/sec-filings/fate/0001193125-26-073699.htm, https://www.metatrader.com/en/symbols/nasdaq/fate/documents/234740-annual-report-fy2025 |
| 产能 | 逾40,000平方英尺的GMP生产设施，可支持临床开发各阶段及初步商业化 | https://ir.fatetherapeutics.com/node/13906/html, https://stocklight.com/stocks/us/nasdaq-fate/fate-therapeutics/annual-reports/nasdaq-fate-2026-10K-26682010.pdf |
| 认证 | 由加利福尼亚州卫生服务部食品药品分局颁发的药品生产许可证 | https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-opening-its-cgmp-manufacturing |
| 监管批准 | FDA已批准多项研究性新药（IND）申请；MHRA和EMA已授权FT819临床试验 | https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-reports-third-quarter-2025-financial-results, https://last10k.com/sec-filings/fate/0001193125-26-073699.htm |
| 生产基地 | 美国加利福尼亚州圣地亚哥 | https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-opening-its-cgmp-manufacturing |
| 员工人数 | 截至2025年12月31日有161名全职员工 | https://www.metatrader.com/en/symbols/nasdaq/fate/documents/234740-annual-report-fy2025 |
| 营收 | 2025财年$664.6万 | https://www.metatrader.com/en/symbols/nasdaq/fate/documents/234740-annual-report-fy2025 |

独立来源: last10k.com, metatrader.com, stocklight.com

## 技术

- [NK 细胞与 CAR-NK 疗法](https://cn.bioecon.ru/technology/nk-cell-car-nk-therapy/)